<DOC>
	<DOCNO>NCT00720447</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy monoclonal antibody therapy donor stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . PURPOSE : This phase II trial study donor stem cell transplant treat patient mantle cell lymphoma .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine progression-free survival patient mantle cell lymphoma undergo low-intensity allogeneic stem cell transplantation . Secondary - Determine overall survival patient . - Determine toxicity way adverse event profile regimen patient . OUTLINE : This multicenter study . - Reduced intensity conditioning : Patients receive carmustine IV 2 hour day -6 , etoposide IV 1 hour cytarabine IV 15 minute day -5 -2 , alemtuzumab IV 2 hour day -5 -1 , melphalan IV day -1 . - Donor stem cell transplant : Patients undergo stem cell transplantation day 0 filgrastim ( G-CSF ) -mobilized peripheral blood stem cell bone marrow stem cell . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV orally day -1 30 taper day 100 . - Donor lymphocyte infusion ( DLI ) therapy : Patients evidence disease progression , mixed chimerism , low level residual disease undergo DLI every 3 month 15 month absence GVHD . After completion study , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis mantle cell lymphoma No relapsed progressive disease Achieved least partial remission follow induction chemotherapy HLAmatched donor available Blood sample patient donor available chimerism study No central nervous system involvement PATIENT CHARACTERISTICS : ECOG performance status 24 Considered fit transplant treat physician Serum bilirubin ≤ 1.5 time upper limit normal Alkaline phosphatase ≤ 2 time normal Creatinine clearance ≥ 50 mL/min Ejection fraction &gt; 50 % ( inadequate cardiac function ) Not pregnant nursing Negative pregnancy test No symptomatic respiratory compromise No serious concurrent disease would preclude allograft No known serological positivity hepatitis B , hepatitis C , HIV No history psychological illness condition would affect compliance No previous malignancy within past 5 year except nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>